Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies

Exclusion Criteria

• •1\. Accompanied by other uncontrolled malignant tumors;
• •2\. Previously received chimeric antigen receptor therapy or other transgenic T cell therapy;
• •3\. Known history of HIV or hepatitis B (HBsAg positive and HBV DNA reaching the detection limit) or hepatitis C virus (anti HCV positive) infection;
• •4\. Participants with a history of CNS lymphoma, malignant cells in cerebrospinal fluid, or brain metastases;
• •5\. The researcher believes that there are any other factors that are not suitable for the study participants to enter this trial.